KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Cash & Equivalents for 6 consecutive years, with $495.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 22.93% year-over-year to $495.7 million, compared with a TTM value of $495.7 million through Sep 2025, down 22.93%, and an annual FY2024 reading of $156.3 million, up 2595.26% over the prior year.
  • Cash & Equivalents was $495.7 million for Q3 2025 at AbCellera Biologics, up from $92.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.0 billion in Q2 2022 and bottomed at $5.8 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $493.5 million, with a median of $517.7 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 98.5% in 2023, then soared 2595.26% in 2024.
  • Year by year, Cash & Equivalents stood at $476.1 million in 2021, then dropped by 18.82% to $386.5 million in 2022, then tumbled by 98.5% to $5.8 million in 2023, then skyrocketed by 2595.26% to $156.3 million in 2024, then surged by 217.08% to $495.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for ABCL at $495.7 million in Q3 2025, $92.4 million in Q2 2025, and $605.3 million in Q1 2025.